

<b>PATIENT GROUP DIRECTION (PGD) FOR</b>		
<b>PGD 60 (S)</b>	<b>EMLA CREAM 5% (LIDOCAINE 2.5% AND PRILOCAINE 2.5%) TO BE USED AS TOPICAL LOCAL ANAESTHETIC PRIOR TO VASECTOMY</b>	<b>POM</b>

**YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD  
BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT**

**PROFESSIONAL(S) TO WHICH THIS PGD APPLIES:**

Nursing and Midwifery Council (NMC) Registered Nurses working in Integrated Sexual Health Services (ISHS)

<b>CLINICAL CONDITION</b>	
<b>Indication</b>	Topical local anaesthetic for genital skin to be used prior to injection of local anaesthetic pre-vasectomy procedure.
<b>Inclusion Criteria</b>	Prior to procedure requiring topical local anaesthetic.
<b>Exclusion Criteria</b>	<ul style="list-style-type: none"> <li>• Known hypersensitivity to local anaesthetic or any of the ingredients in EMLA Cream.</li> <li>• Atopic dermatitis at site of application</li> <li>• Inflamed or broken skin at the site of application</li> </ul>
<b>Cautions</b>	<p>If client known to have methemoglobinemia seek advice from a non-medical prescriber or a doctor.</p> <p>EMLA may interact with:</p> <ul style="list-style-type: none"> <li>• Anti-arrhythmics, increased myocardial depression</li> <li>• Antipsychotics, increased risk of ventricular arrhythmias when lidocaine given with antipsychotics that increase the QT interval</li> <li>• Betablockers, increased myocardial depression when given with betablockers and increased risk of lidocaine toxicity when given with propanolol</li> </ul> <p>In general, given the small exposure of prilocaine and lidocaine from a single 5g dose of EMLA, pharmacokinetic interactions are not of clinical significance.</p> <p>See eBNF and/or SPC for full list of drug interactions prior to use.</p>
<b>Action if patient declines or is excluded</b>	<p>If a patient is excluded or declines treatment, document in patient's records.</p> <p>Procedure may be performed without topical local anaesthetic.</p>

DRUG DETAILS	
<b>Name, Form &amp; Strength of Medicine</b>	EMLA Cream 5% (lidocaine 2.5% and Prilocaine 2.5%) 5g tubes
<b>Route/Method</b>	Apply or advise client to apply topically in a mound to the scrotal skin and cover with the occlusive dressing as per the vasectomy booklet diagram/written instructions supplied by the clinic.
<b>Off-Label Use</b>	Not applicable. Treatment is within the marketing authorisation.
<b>Dosage/Frequency</b>	5g tube – apply whole amount 1 hour before the appointment time under an occlusive dressing
<b>Quantity</b>	One tube [5g]
<b>Total Daily Dose</b>	5g cream application
<b>Duration of Treatment</b>	Single treatment - apply 1 hour prior to vasectomy procedure as directed
<b>Advice to Patient/Carer</b>	Side effects include administration site reactions such as transient paleness, redness, oedema, itching, burning sensation and localised lesions.  If side effects become troublesome or do not resolve within 48 hours then medical advice should be obtained from vasectomy service or alternatively from GP.
<b>Advice to Staff</b>	Explain treatment and side effects. <ul style="list-style-type: none"> <li>Do not rub cream in.</li> <li>Do not spread cream.</li> <li>Occlusive dressing to be left in place for up to 1 hour prior to procedure.</li> </ul> Self-check correct product, dose selected and check expiry date.  <b>Safeguarding:</b> Where there are any safeguarding concerns refer to local policies for safeguarding adults and children and/or seek advice from the safeguarding lead/team in the organisation. Document the concern and outcome in the healthcare record. DCHS: Safeguarding adults and children policies on DCHS share point. DCHS Safeguarding Team: 01773 850000.
<b>Record</b>	All details should be recorded in the notes. <ul style="list-style-type: none"> <li>Patient's name, address, date of birth.</li> <li>Assessment of competency to consent (including Gillick competency)</li> <li>Consent obtained and documented as per <a href="#">DCHS Consent Policy</a></li> <li>Allergy</li> <li>Confirm history and family history checked</li> <li>Current illness/medication</li> </ul>

	<ul style="list-style-type: none"> <li>• PGD followed</li> <li>• Drug, brand, form and dose</li> <li>• Batch and expiry details</li> <li>• Practitioner's identifier</li> <li>• Advice given to client (including side effects, contraception etc.)</li> <li>• Referral arrangements (including self-care)</li> <li>• Any other relevant details of consultation</li> </ul> <p>Entries should be written in black ink and dated, timed and signed or recorded electronically if applicable.</p>
--	---

<b>REFERRAL ARRANGEMENTS AND AUDIT TRAIL</b>	
<b>Referral Arrangements</b>	The practitioner is expected to use their clinical judgement and refer patients to an appropriate senior or medical doctor for advice and management as they see fit.
<b>Records/Audit Trail</b>	<ul style="list-style-type: none"> <li>• Document in client's record</li> </ul>

<b>CHARACTERISTICS OF STAFF</b>	
<b>Qualifications</b>	A registered nurse working within ISHS who is deemed competent by their clinical line manager and authorised by their professional lead to undertake the clinical assessment of a patients leading to the identification of those suitable for management under this PGD.
<b>Additional Local Training</b>	<ul style="list-style-type: none"> <li>• Has undertaken the local training programme on the process, responsibilities and scope of PGDs.</li> <li>• Has undertaken local training based on the use of this PGD</li> <li>• Has undertaken training in recognition of and treatment of anaphylaxis including basic life support in the last year</li> <li>• Has undertaken training in recognition of the management of patients requesting a vasectomy (male sterilisation procedure).</li> <li>• Has undertaken Safeguarding Adults Level 2 in the last 3 years.</li> </ul>
<b>Continuing Training &amp; Education</b>	<p>The nurse should be aware of any change to the recommendations for the medicines listed.</p> <p>It is the responsibility of the individual to keep up-to-date with continued professional development and to work within the limitations of individual scope of practice.</p>

<b>ADDITIONAL INFORMATION</b>	
<b>References</b>	<ol style="list-style-type: none"> <li>1. British National Formulary <a href="http://www.bnf.org">http://www.bnf.org</a></li> <li>2. Summary of product characteristics <a href="http://emc.medicines.org.uk">http://emc.medicines.org.uk</a></li> </ol>

<b>Storage</b>	<p>Medicines must be stored securely according to national guidelines and in accordance with the product SPC.</p> <p>However, in the event of an inadvertent or unavoidable deviation of temperature follow the <a href="#">Temperature Monitoring of Medicines Storage Rooms SOP</a>.</p>
<b>Drug Interactions</b>	<p>Comprehensive lists of drug interactions are not described in each PGD, only the most significant are listed.</p> <p>A detailed list of drug interactions is available in the SPC, which is available from the electronic Medicines Compendium website: <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> or the eBNF <a href="http://www.bnf.org">www.bnf.org</a>.</p>
<b>Identification &amp; Management of Adverse Reactions</b>	<p>A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> and eBNF <a href="http://www.bnf.org">www.bnf.org</a></p>
<b>Management of and Reporting Procedure for Adverse Reactions</b>	<ul style="list-style-type: none"> <li>Healthcare professionals and individuals are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: <a href="http://yellowcard.mhra.gov.uk">http://yellowcard.mhra.gov.uk</a></li> <li>Record all adverse drug reactions (ADRs) in the individual's medical record</li> <li>Report any adverse reactions via DCHS incident policy.</li> </ul>





<b>THIS PGD WAS REVIEWED BY:</b>	
<b>Name</b>	<b>Position</b>
Sharon Boden	Quality and Training Lead Integrated Sexual Health Services
Debby Railton	Advanced Pharmacist

<b>REVIEW</b>		
<b>Comments</b>	<b>Name</b>	<b>Position</b>
<p><b>March 2022</b></p> <ul style="list-style-type: none"> <li>Minor rewording</li> <li>Removal of pharmacokinetically interacting medicines given clinical insignificance and minimal systemic exposure to lidocaine and prilocaine from single 5g EMLA dose</li> </ul>	<p>Sharon Boden</p> <p>Ben Dorward</p>	<p>Quality Manager ISHS</p> <p>Advanced Pharmacist</p>

**PATIENT GROUP DIRECTION AUTHORISATION**

PGD approved by PGD Working Group on 24 March 2022

This PGD is authorised for use on behalf of DCHS by the following signatories.

Position of signatory	Name	Signature	Date
Deputy Chief Nurse	Jo Hunter		14/04/2022
Head of Medicines Management	Kate Needham		14/04/2022
Medical Director	Dr Ben Pearson		14/04/2022
Vasectomy Lead	Dr Andrea Watson		14/04/2022

## PRACTITIONER AUTHORISATION SHEET

**PGD:** 60(S) Emla Cream (Adult) for Vasectomy

**Version & Expiry Date:** v5, Expiry: 31 March 2025

### Practitioner

By signing this PGD you are indicating that you agree to its contents and that you will work within it.

PGDs do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.

Name	Designation	Signature	Date

### Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of Derbyshire Community Health Services for the above named health care professionals who have signed the PGD to work under it.

Name	Designation	Signature	Date

### Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet must be retained to serve as a record of those practitioners authorised to work under this PGD.